14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $8M | -$346M | 0.0% | -4974.3% | -$280M | — | $199M |
| 2024 | $0 | -$234M | — | — | -$184M | — | $143M |
| 2023 | $0 | -$182M | — | — | -$157M | — | $149M |
| 2022 | $9M | -$125M | 0.0% | -1368.9% | -$104M | — | $57M |
| 2021 | $18M | -$79M | 0.0% | -428.4% | -$72M | — | $176M |
| 2020 | $32M | -$29M | 0.0% | -97.3% | -$51M | — | $45M |
| 2019 | $7M | -$42M | 0.0% | -627.0% | -$6M | $16M | $25M |
| 2018 | — | -$34M | — | — | -$35M | $15M | $68M |
| 2017 | — | -$31M | — | — | -$29M | $7M | $20M |
| 2016 | — | -$23M | — | — | — | — | $17M |
| 2015 | — | -$16M | — | — | — | — | $59M |
| 2014 | — | $13M | — | — | — | — | $72M |
| 2013 | — | $12M | — | — | — | — | $38M |
| 2012 | — | -$4M | — | — | — | — | $60M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$102M | — | — | -$89M | — | $546M |
| Dec '25 | $0 | -$105M | — | — | -$82M | — | $199M |
| Sep '25 | $0 | -$91M | — | — | -$72M | — | $105M |
| Jun '25 | $0 | -$85M | — | — | -$64M | — | $135M |
| Mar '25 | $8M | -$65M | 0.0% | -969.8% | -$62M | — | $117M |
| Dec '24 | $0 | -$66M | — | — | -$55M | — | $143M |
| Sep '24 | $0 | -$63M | — | — | -$50M | — | $88M |
| Jun '24 | $0 | -$58M | — | — | -$33M | — | $137M |
| Mar '24 | $0 | -$48M | — | — | -$46M | — | $59M |
| Dec '23 | — | -$45M | — | — | -$35M | — | $149M |
| Sep '23 | — | -$48M | — | — | -$49M | — | $100M |
| Jun '23 | — | -$47M | — | — | -$35M | — | $65M |
| Mar '23 | — | -$42M | — | — | -$37M | — | $70M |
| Dec '22 | $0 | -$37M | — | — | -$34M | — | $57M |
| Sep '22 | $132000 | -$37M | 0.0% | -28884.8% | -$31M | — | $103M |
| Jun '22 | $536000 | -$31M | 0.0% | -5655.8% | -$17M | — | $370M |
| Mar '22 | $9M | -$20M | 0.0% | -198.1% | -$19M | — | $117M |
| Dec '21 | $4M | -$26M | 0.0% | -664.7% | -$21M | — | $176M |
| Sep '21 | $8M | -$15M | 0.0% | -192.0% | -$15M | — | $88M |
| Jun '21 | $2M | -$22M | 0.0% | -1014.3% | -$14M | — | $83M |
How the market has priced XENE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Xenon Pharmaceuticals Inc.'s revenue has declined 25.3% per year. These are computed facts, not advice.
As of FY2025, Xenon Pharmaceuticals Inc. reported — of total debt against $199M of cash.
In FY2025, gross margin was —, operating margin -4974.3%, and net margin -4612.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.